Recently, it has been shown that either activating Nav1.1 or blocking Nav1.6 can reduce seizure occurrence in a zebrafish model of Dravet syndrome [23], demonstrating the therapeutic potential of targeting these sodium channels. The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.